Skip to main content

Table 3 Comparison of clinical features of patients with rheumatoid arthritis with or without serum citrullinated inter-alpha-trypsin inhibitor heavy chain 4

From: Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis

  Total Citrullinated ITIH4 p Value
+
No. of patients (%) 60 49 (82%) 11 (18%)  
Age, years 52.2 ± 1.9 51.3 ± 2.2 55.9 ± 3.9 0.355
Females, n (%) 48 (80%) 38 (78%) 10 (91%) 0.317
DAS28-CRP score 3.9 ± 0.2 4.1 ± 0.2 3.3 ± 0.4 0.040
CRP, mg/dl 2.18 ± 0.30 2.46 ± 0.34 0.93 ± 0.56 0.047
Anti-CCP antibodies, U/ml 131.6 ± 21.6 138.9 ± 24.6 93.4 ± 39.0 0.462
 Positive, n (%) 46 (82%) 39 (83%) 7 (78%) 0.709
RF, U/ml 210.6 ± 46.1 242.3 ± 55.0 69.5 ± 35.5 0.011
MMP-3, ng/ml 198.5 ± 21.8 214.7 ± 25.7 127.9 ± 20.1 0.122
PSL use, n (%, mean dose in mg/day) 51 (85%, 6.9) 41 (84%, 7.1) 10 (91%, 6.4) 0.544
MTX use, n (%, mean dose in mg/week) 40 (67%, 10.1) 31 (63%, 10.1) 10 (91%, 10.0) 0.075
  1. Abbreviations: ITIH4 Inter-alpha-trypsin inhibitor heavy chain 4, DAS28-CRP Disease Activity Score in 28 joints as measured by C-reactive protein, CRP C-reactive protein, CCP Cyclic citrullinated peptide, RF Rheumatoid factor, MMP-3 Matrix metalloproteinase 3, PSL Prednisolone, MTX Methotrexate
  2. Values are mean ± SEM. The cutoff value for positive citrullinated ITIH4 was band intensity of 0.46, representing the mean + 3 SD of healthy subjects